Non-interventional Study on the Use of ILARIS4 Canakinumab Among Familial Mediterranean Fever and Stills Disease Patients Across Europe and Israel

What this Trial Is About

Researchers are evaluating the treatment patterns, long-term clinical outcomes, and demographic characteristics of patients diagnosed with Familial Mediterranean fever FMF and Stills disease, including systemic juvenile idiopathic arthritis SJIA and adult-onset Stills disease AOSD. This observational study focuses on patients who have received canakinumab treatment for at least six months to understand its use in real-world settings across Europe and Israel. The study includes three groups of patients those with FMF, SJIA, and AOSD, all of whom have been treated with canakinumab for at least six months. It tracks treatment use and responses over time, including the use of other biologic agents like anakinra and tocilizumab. The research assesses various outcomes up to three years after starting canakinumab, including disease activity, remission status, steroid usage, treatment switches, hospitalizations, medical visits, and quality of life. Participants medical records and data will be reviewed for clinical characteristics, treatments, hospitalizations, diagnostic and laboratory tests, and quality of life measures over a follow-up period of up to three years. The study aims to measure how many patients achieve inactive disease or remission and track other treatment responses. Data collection includes information before, during, and after canakinumab treatment to provide a comprehensive understanding of patient outcomes and long-term management.

A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients